NewAmsterdam Pharma Company NAMS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's accounts payable?
- NewAmsterdam Pharma Company (NAMS) reported accounts payable of $8.09M in Q1 2026.
- How has NewAmsterdam Pharma Company's accounts payable changed year-over-year?
- NewAmsterdam Pharma Company's accounts payable increased by 32.9% year-over-year, from $6.09M to $8.09M.
- What is the long-term trend for NewAmsterdam Pharma Company's accounts payable?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's accounts payable has grown at a 39.1% compound annual growth rate (CAGR), from $6.56M to $24.58M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.